CareDx, Inc. Investigation

We are investigating possible false claims, accounting and reporting practices and breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of CareDx, Inc. (NASDAQ: CDNA) (“CareDx” or the “Company”), which has led to investigations by the U.S. Department of Justice (“DOJ”) and the Securities and Exchange Commission (“SEC”) concerning “certain business practices related to [CareDx’s] kidney testing and phlebotomy services.”

On October 28, 2021, the Company filed a Form 10Q which disclosed that it had recently received a False Claims Act (“FCA”) civil investigative demand from the DOJ as well as a subpoena from the SEC related to the Company’s kidney testing and phlebotomy services “as well as certain of [CareDx’s] accounting and public reporting practices.” The Company also disclosed that an additional unnamed state regulatory agency has also made an information request, and it is possible that the Company will “receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters.”

WeissLaw LLP is investigating whether CareDx’s Board of Directors: failed to establish and maintain a comprehensive system of internal controls over certain of its kidney testing and phlebotomy services; failed to establish and maintain a comprehensive system of internal controls over its accounting and public reporting practices; and violated federal securities laws or breached fiduciary duties owed to CareDx and its shareholders.

If you own CDNA shares and wish to discuss this investigation, please visit our website at https://www.weisslaw.co/news-and-cases/cdna or contact Josh Rubin at stocks@weisslaw.co or (212) 682-3025. There is no cost or obligation to you.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients. For more information about the firm, please go to: http://www.weisslaw.co

Other Cases

April 4, 2024

Doma Holdings Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Doma Holdings Inc. (“Doma” or the “Company”) (NYSE: DOMA), in connection with its acquisition by Title Resources Group. Under the merger agreement, the Company’s shareholders will receive $6.29 per share.

Join Case →

April 4, 2024

Fusion Pharmaceuticals Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Fusion Pharmaceuticals Inc. (“Fusion” or the “Company”) (NASDAQ: FUSN) in connection with its proposed acquisition by a subsidiary of AstraZeneca. Under the merger agreement, the Company’s shareholders will receive $21.00 per share at closing plus a non-transferable contingent value right (“CVR”) of $3.00 per share payable upon the achievement of a specified regulatory milestone.

Join Case →

April 4, 2024

Landos Biopharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Landos Biopharma, Inc. (“Landos” or the “Company”) (NASDAQ: LABP), in connection with its acquisition by AbbVie Inc. (NYSE: ABBV). Under the merger agreement, the Company’s shareholders will receive $20.42 per share plus one non-tradable contingent value right (“CVR”) per share with avalue of up to $11.14 per share, subject to the achievement of a clinical development milestone.

Join Case →